Taiwan · Delayed Price · Currency is TWD StemCyte International Company Description
StemCyte International, Ltd., together with its subsidiaries, operates cord blood cell banks in the United States and Taiwan.
The company offers public donation umbilical cord blood transplantation and private umbilical cord blood storage services; and cell products and services.
It also engages in the research and development of biotechnology and cell-based new drugs; and supply of cellular materials.
In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders, as well as for post-covid, acute stroke, and cerebral palsy.
Further, it develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies.
The company was founded in 1997 and is based in Taipei, Taiwan. StemCyte International, Ltd. is a subsidiary of Diamond Biofund Inc.
| Country | Cayman Islands |
| Founded | 1997 |
| Industry | Miscellaneous Health And Allied Services, Not Elsewhere Classified |
| CEO | Tong-Young Lee |
Contact Details
Address: No. 508, Zhongxiao East Road Taipei, 115 Taiwan | |
| Phone | 886 2 2601 3013 |
| Website | stemcytebio.com |
Stock Details
| Ticker Symbol | 4178 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Tong-Young Lee | Chief Executive Officer |